Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
作者信息
Wang Fei, Duan Xue-Ning, Ling Rui, Yu Zhi-Gang
机构信息
Department of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250033, China.
Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
出版信息
Chin Med J (Engl). 2021 Jun 10;134(14):1655-1657. doi: 10.1097/CM9.0000000000001502.
Abstract
摘要
相似文献
1
Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 Jun 10;134(14):1655-1657. doi: 10.1097/CM9.0000000000001502.
2
Clinical practice guidelines for pre-operative evaluation of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 May 19;134(18):2147-2149. doi: 10.1097/CM9.0000000000001520.
3
Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 Apr 28;134(9):1009-1013. doi: 10.1097/CM9.0000000000001498.
4
Clinical practice guidelines for modified radical mastectomy of breast cancer: Chinese Society of Breast Surgery (CSBrs) practice guidelines 2021.
Chin Med J (Engl). 2021 Apr 1;134(8):895-897. doi: 10.1097/CM9.0000000000001412.
5
Clinical practice guidelines for diagnosis and treatment of patients with non-puerperal mastitis: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021.
Chin Med J (Engl). 2021 May 19;134(15):1765-1767. doi: 10.1097/CM9.0000000000001532.
6
Clinical practice guidelines for endoscopic breast surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 Oct 19;134(21):2532-2534. doi: 10.1097/CM9.0000000000001592.
7
Clinical practice guidelines for post-mastectomy breast reconstruction: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 Sep 22;134(19):2272-2274. doi: 10.1097/CM9.0000000000001611.
8
Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2022.
Chin Med J (Engl). 2023 Aug 20;136(16):1894-1896. doi: 10.1097/CM9.0000000000002780. Epub 2023 Jul 14.
9
Clinical practice guidelines for pregnancy-associated breast cancer: Chinese society of breast surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 Aug 27;134(20):2395-2397. doi: 10.1097/CM9.0000000000001686.
10
Clinical practice guideline for breast-conserving surgery in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 Jun 16;134(18):2143-2146. doi: 10.1097/CM9.0000000000001518.
引用本文的文献
1
Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022.
Transl Breast Cancer Res. 2023 Jan 31;4:2. doi: 10.21037/tbcr-22-50. eCollection 2023.
2
Analysis of Breast Cancer Screening Results and Influencing Factors of Breast Cancer in Guangdong Province from 2017 to 2021.
J Epidemiol Glob Health. 2024 Mar;14(1):131-141. doi: 10.1007/s44197-023-00176-3. Epub 2024 Jan 15.
3
Will Absolute Risk Estimation for Time to Next Screen Work for an Asian Mammography Screening Population?
Cancers (Basel). 2023 Apr 29;15(9):2559. doi: 10.3390/cancers15092559.
本文引用的文献
1
Clinical practice guideline of BRCA1/2 testing for patients with breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021.
Chin Med J (Engl). 2021 Jun 4;134(13):1516-1518. doi: 10.1097/CM9.0000000000001587.
2
Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.
Chin Med J (Engl). 2021 Apr 1;134(8):886-894. doi: 10.1097/CM9.0000000000001410.
3
[Guideline on next-generation sequencing-based BRCA1/2 testing (2019)].
Zhonghua Bing Li Xue Za Zhi. 2019 Sep 8;48(9):670-677. doi: 10.3760/cma.j.issn.0529-5807.2019.09.002.
4
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
JAMA. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885.
5
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.
6
10-year performance of four models of breast cancer risk: a validation study.
Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21.
7
Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model.
BMC Cancer. 2019 Feb 7;19(1):128. doi: 10.1186/s12885-019-5321-1.
8
[Report of cancer epidemiology in China, 2015].
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005.
9
Assessment of performance of the Gail model for predicting breast cancer risk: a systematic review and meta-analysis with trial sequential analysis.
Breast Cancer Res. 2018 Mar 13;20(1):18. doi: 10.1186/s13058-018-0947-5.
10
Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry.
Breast Cancer Res. 2016 Dec 8;18(1):124. doi: 10.1186/s13058-016-0786-1.
Zotero 插件